Eikon Therapeutics completed an upsized $381 million IPO to bankroll clinical development of its oncology pipeline, including its TLR7/8 co‑agonist EIK‑1001 and PARP‑focused programs. The company, which has raised over $1 billion in private rounds, positioned proceeds for Phase 2/3 work across melanoma, non‑small cell lung cancer and other solid tumors and signaled plans to advance brain‑penetrant and WRN‑targeted assets. The offering is being read as part of a broader and growing appetite for biotech IPOs after a slow period; Eikon’s public debut will be watched as a bellwether for investor risk tolerance in capital‑intensive oncology development.